BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Hold at Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Saturday.

BCRX has been the topic of a number of other research reports. Citizens Jmp upped their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a "market outperform" rating in a research report on Thursday. Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an "outperform" rating on the stock in a research report on Thursday. Royal Bank Of Canada dropped their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a research report on Friday, January 30th. Needham & Company LLC dropped their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Wednesday. Finally, Weiss Ratings upgraded BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research report on Wednesday, March 4th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $20.70.

BioCryst Pharmaceuticals Stock Down 3.1%

BCRX opened at $8.62 on Friday. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The company has a market cap of $2.19 billion, a P/E ratio of -4.84 and a beta of 0.57. The firm's 50-day moving average price is $9.08 and its 200-day moving average price is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the company earned $0.20 EPS. The business's revenue was up 7.5% compared to the same quarter last year. On average, research analysts anticipate that BioCryst Pharmaceuticals will post 0.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Alane P. Barnes sold 150,000 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC lifted its holdings in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Farther Finance Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 8,109 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 2,115 shares during the period. Finally, Vestmark Advisory Solutions Inc. acquired a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.